课题基金 / 基金详情

Novel Inhibitors of Nuclear Receptor Function

Novel Inhibitors of Nuclear Receptor Function
核受体功能的新型抑制剂
批准号:
6778270
负责人:
Rodney Kiplin Guy
金额:
$29.43万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-01 至 2006-08-31

项目摘要

项目成果

Rodney Kiplin Guy的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Provided by Applicant) The broad, long-term objectives of this proposal are the development of novel inhibitors that specifically prevent the interaction of nuclear receptors with their coactivating proteins through their NR box binding site and thus functionally block transcriptional activation by nuclear receptors. The Specific Aims of this proposal are 1) To use conformationally constrained peptide inhibitors of the interaction of the human thyroid receptor (hTRf3 1) with the glucocorticoid receptor interacting protein 1 (GRIP 1) to evaluate the structure-activity relationships of the individual leucine side chains of the LXXLL triad (NR box) of GRIP 1; 2) to design and synthesize sets of non-peptide compounds that mimic the side chain presentation of the LXXLL triad in order to establish viable scaffolds for discovery library synthesis that present their side chains in the correct geometry; 3) to synthesize libraries of non-peptide inhibitors and screen these to find specific inhibitors for nuclear receptor coactivator interactions; 4) to expand the biochemical model systems under consideration to include the estrogen receptor (ER), androgen receptor (AR), and peroxisome proliferator-activated receptor (PPAR) thus allowing the study of the specificity of inhibition of the nuclear receptor coactivator interactions; and 5) to optimize any active inhibitors of nuclear receptor function for maximal potency against particular receptors and selectivity among receptors. The health relatedness of this project is that the new method of inhibiting nuclear receptor function has the potential to provide new therapies for diseases mediated by nuclear receptors which include cancer, cardiovascular disease, diabetes, and osteoporosis - diseases currently treated with drugs based upon hormone structure. The research design is the use of molecular design and combinatorial chemistry to develop non-peptide inhibitors. The methods to be used are chemical synthesis, biochemical screening, structure determination, molecular design, and cellular biology evaluation of physiological effect.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chemical Biology of the Control of Neddylation by DCN1
  • 批准号:
    10655433
  • 项目类别:
  • 资助金额:
    $62.32万
  • 财政年份:
    2019
  • 负责人:
    Rodney Kiplin Guy
  • 依托单位:
Chemical Biology of the Control of Neddylation by DCN1
  • 批准号:
    10461734
  • 项目类别:
  • 资助金额:
    $62.32万
  • 财政年份:
    2019
  • 负责人:
    Rodney Kiplin Guy
  • 依托单位:
Chemical Biology of the Control of Neddylation by DCN1
  • 批准号:
    10198872
  • 项目类别:
  • 资助金额:
    $63.59万
  • 财政年份:
    2019
  • 负责人:
    Rodney Kiplin Guy
  • 依托单位:
Development of Novel Therapeutics for Leishmaniasis
海外基金